The observation that accelerated growth of lesions harboring H-RAS mutations following exposure to B-RAF inhibitors was blocked by subsequent combined B-RAF/MEK inhibitor treatment is of particular note [26], and further supports the efficacy of MEK inhibitors and their potential role in metastatic melanoma [27],[28]. This evidence concerns the gene BRAF and metastatic melanoma.